Pear Therapeutics, Inc. (NASDAQ:PEAR) Receives Consensus Rating of “Buy” from Analysts

Pear Therapeutics, Inc. (NASDAQ:PEARGet Rating) has been assigned an average rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.55.

A number of brokerages have recently commented on PEAR. Chardan Capital dropped their price target on Pear Therapeutics from $16.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, May 17th. Citigroup raised their target price on Pear Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, May 17th. Finally, Zacks Investment Research raised Pear Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research report on Friday, April 1st.

Shares of Pear Therapeutics stock traded down $0.09 on Friday, hitting $3.90. The stock had a trading volume of 328,184 shares, compared to its average volume of 330,472. Pear Therapeutics has a twelve month low of $2.81 and a twelve month high of $14.60. The company has a 50 day moving average price of $4.68.

Pear Therapeutics (NASDAQ:PEARGet Rating) last issued its quarterly earnings results on Monday, March 28th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The company had revenue of $1.32 million during the quarter. Sell-side analysts predict that Pear Therapeutics will post -0.87 EPS for the current year.

A number of institutional investors have recently modified their holdings of PEAR. TB Alternative Assets Ltd. acquired a new stake in Pear Therapeutics during the 4th quarter worth about $12,846,000. BerganKDV Wealth Management LLC acquired a new stake in Pear Therapeutics during the 4th quarter worth about $28,000. 5AM Venture Management LLC acquired a new stake in Pear Therapeutics during the 4th quarter worth about $115,517,000. Roble Belko & Company Inc acquired a new stake in Pear Therapeutics during the 4th quarter worth about $28,000. Finally, Arboretum Ventures Inc. acquired a new stake in shares of Pear Therapeutics in the 4th quarter valued at about $67,326,000. Hedge funds and other institutional investors own 53.66% of the company’s stock.

About Pear Therapeutics (Get Rating)

Pear Therapeutics, Inc, a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia.

Recommended Stories

Analyst Recommendations for Pear Therapeutics (NASDAQ:PEAR)

Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.